ANNX News & Events

Biogen (BIIB) has agreed to acquire Apellis Pharmaceuticals (APLS) for $41 per share, bringing complement inhibitors Syfovre and Empaveli into its portfolio, with Syfovre's $589M in 2025 sales viewed as the primary value driver, Chardan tells investors in a research note. The deal underscores strong pharma interest in the complement pathway, particularly in geographic atrophy, and reads positively to peers such as Annexon (ANNX) and Ocugen (OCGN), potentially catalyzing further partnership or licensing activity in the space, the firm says. Chardan has a Buy rating and $16 price target on shares of Annexon.

"We're energized by this defining period for Annexon. Two decades of C1q and classical complement pathway research have enabled our bold mission of pioneering a new class of targeted immunotherapies that reshape how neuroinflammation is treated. Today, our scientific platform has translated into two late stage registrational programs with the potential to improve the lives of millions in large, underserved markets worldwide," said Douglas Love, president and chief executive officer of Annexon. "Leveraging one mechanism to stop neuroinflammation at its source, vonaprument is designed to protect photoreceptor neurons to preserve vision in GA, while tanruprubart is designed to protect peripheral nerves to support faster, more complete and durable recovery in GBS."

Annexon highlighted its 2026 strategic priorities and key milestones for its lead programs. Key highlights include: Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barre Syndrome; BLA Submission with U.S./European Data Planned in 2026; Vonaprument Pivotal Phase 3 Topline Data for Dry AMD with Geographic Atrophy on Track for Second Half of 2026 Evaluating Unprecedented Effect on Vision Protection; Proof-of-Concept Data for ANX1502, the First Oral C1 Inhibitor for Autoimmune Disease, Expected in 2026